Bench Side Story continues with Dr Michael Collins, a kidney transplant specialist at Royal Adelaide Hospital in South Australia.
He is the Principal Investigator of a trial called the BEST Fluids trial, which has recently been completed and showed which was the best treatment in terms of intravenous fluids to use for kidney transplant recipients.
Since he was a young child, Dr Collins, has been interested in kidney failure and kidney transplants in particular. His father was also a kidney specialist, and he used to sit by the phone when his father, was on call and ringing people who were being offered a kidney transplant. The joy in their voices through this interaction created a lasting and profound impact on Dr Collins. This carried through his career and today he continues to seek better outcomes for Kidney patients.
-
Systems genetics to determine risk of developing diabetes complications
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Health impacts of donor milk for pre-term babies
Professor Alice Rumbold is Theme Leader of SAHMRI Women and Kids, managing a multidisciplinary research team focussed on improving health outcomes for women, babies and families. She also holds an affiliate position as a Research Leader within the Robinson Research Institute at the University of Adelaide.
An epidemiologist and health services researcher, she is internationally renowned for her leadership of large-scale clinical trials, epidemiological studies and systematic review activities to improve perinatal and reproductive health care. She is passionate about improving health outcomes for women and babies, particularly those experiencing vulnerability. Her current research interests include preterm birth, breastfeeding, human milk banking and infertility
